Form 4: Lexicon Pharmaceuticals Director Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Raymond Debbane, a director of Lexicon Pharmaceuticals, acquired stock options and restricted stock units on May 13, 2024.
Summary
- On May 13, 2024, Raymond Debbane, a director at Lexicon Pharmaceuticals, acquired 44,906 stock options with an exercise price of $1.79.
- These options vest in equal installments over three years from the grant date and expire on May 13, 2034.
- Debbane also acquired 36,810 restricted stock units (RSUs) that vest 100% on the first anniversary of the grant date.
- Each RSU represents the right to receive one share of Lexicon Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock option and RSU grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of stock options and restricted stock units granted to a company director, which is a common practice in executive compensation within the pharmaceutical industry.
Stakeholder Impact
- The granting of stock options and RSUs to a director can align the director's interests with those of the shareholders, potentially incentivizing them to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/13/2024 | Date of transaction: acquisition of stock options and restricted stock units. |
| 05/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.